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(P.M.C.), Royal Hospital for Sick Children, Edinburgh EH9 1LF, United Kingdom; Medical Research
Council Human Reproductive Sciences Unit (N.E.), Edinburgh EH16 4SB, United Kingdom; and Medical
Research Council Centre for Reproductive Health (R.A.A.), University of Edinburgh, Edinburgh EH16 4TJ,
United Kingdom
Context: Cytotoxic treatment may accelerate depletion of the primordial follicle pool, leading to
impaired fertility and premature menopause. Assessment of ovarian damage in prepubertal girls
is not currently possible, but Anti-Mu¨llerian Hormone (AMH) is a useful marker of ovarian reserve
in adults.
Objective: The objective of the studywas to prospectively evaluate AMHmeasurement in children
as a marker of ovarian toxicity during cancer treatment.
Design and Setting: This was a prospective, longitudinal study at a University Hospital.
Patients:Twenty-two females (17prepubertal),medianage4.4 yr (range0.3–15 yr),were recruited
before treatment for cancer.
Main Outcome Measures: AMH, inhibin B, and FSH at diagnosis, after each chemotherapy course
and during follow-up, were measured. Risk of gonadotoxicity was classified as low/medium (n 
13) or high (n 9) basedon chemotherapy agent, cumulative dose, and radiotherapy involving the
ovaries.
Results: Pretreatment AMH was detectable across the age range studied. AMH decreased pro-
gressively during chemotherapy (P  0.0001) in both prepubertal and pubertal girls, becoming
undetectable in 50%of patients, with recovery in the low/medium risk groups after completion of
treatment. In the high-risk group, AMH became undetectable in all patients and showed no re-
covery. Inhibin B was undetectable in most patients before treatment and, with FSH, showed no
clear relationship to treatment.
Conclusion:AMH is detectable in girls of all ages and falls rapidly during cancer treatment in both
prepubertal and pubertal girls. Both the fall during treatment and recovery thereafter variedwith
riskof gonadotoxicity. AMH is therefore a clinically usefulmarker of damage to theovarian reserve
in girls receiving treatment for cancer. (J Clin Endocrinol Metab 97: 2059–2067, 2012)
Survival fromchildhood cancer has improvedmarkedlyover the past few decades, with more than 80% of
children achieving long-term cure (1). However, this im-
proved survival may be associated with gonadal dysfunc-
tion and infertility in adulthood (2). In females, both che-
motherapy and radiotherapymay hasten oocyte depletion
with truncated fecundity andprematuremenopause (2, 3).
An accurate assessment of the risk to individual patients of
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subfertility or infertility before and after cancer treatment
remains a significant challenge.
The effects of radiotherapy are dependent on the dose
received, the fractionation schedule, and the field of irradi-
ation (4, 5). The extent of chemotherapy-induced damage
varies according to the agent administered and is also de-
pendent on the cumulative dose received (2, 5). Assessment
ofovarianfunctioninadulthoodentailsclinicalevaluationof
pubertal status; menstrual history; and biochemical mea-
surements of gonadotrophins (FSH,LH), estradiol, andpro-
gesterone. Although this is helpful in postpubertal children
both before and after treatment, it is not informative prepu-
bertally because the hypothalamic-pituitary-gonadal axis is
quiescent. Counseling young patients and their families on
their fertility prospects is therefore very difficult and is based
on assessment of treatment planned or received. The avail-
ability of a reliable biochemical marker of ovarian reserve,
which was readily detectable in prepubertal girls, would be
an invaluable clinical tool (6).
Anti-Mu¨llerian Hormone (AMH) is produced in the
granulosa cells of growing ovarian follicles up to the early
antral stage (7). The number of these follicles is related to
the size of the primordial follicle pool, and therefore,
AMH represents a marker of ovarian reserve (8). Indeed
AMH demonstrates a rise through childhood and adoles-
cence to a peak in the early 20s, with relative stability
during the third decade of life (6, 9). AMH then declines
during the later reproductive years (10), becoming unde-
tectable before the menopause (11, 12). AMH is stable
across the menstrual cycle (8, 13), adding to its utility in
postpubertal females.
Adults receiving chemotherapydemonstrate a rapidde-
cline in AMH (14, 15), and recent data suggest preche-
motherapy AMH can predict long-term ovarian function
(16). Previous studies (17–19) investigating ovarian re-
serve in adults after treatment for childhood cancer have
demonstrated low AMH concentrations, but the role of
AMH as an early and sensitive marker of gonadotoxicity
in children during and after treatment for cancer has not
previously been investigated.
InhibinB isproducedby largergrowing follicles and,with
FSH, is also a marker of ovarian reserve. Inhibin B concen-
trations are lower in adult womenwho had been treated for
Hodgkin’s lymphoma during childhood (18), and a pilot
study suggested it may have a role as a marker of gonado-
toxicity in prepubertal girls (20). However, their value as
markers of ovarian activity is limited by very low/undetect-
able concentrations before puberty and the need for mea-
surement in the early follicular phase thereafter.
In this prospective cohort study on girls treated for can-
cer, we have measured AMH, inhibin B, and FSH before,
during, and after completion of treatment. The aim of our
study was to evaluate these biochemical measures as po-
tential markers of early gonadotoxicity in young girls
treated for cancer.
Patients and Methods
Female patients diagnosed with malignancy and requiring treat-
ment with pulsed chemotherapy or radiotherapy were enrolled.
All were diagnosed and treated at the Royal Hospital for Sick
Children (Edinburgh, UK) between April 2003 and June 2007.
Patients with Acute Lymphoblastic Leukemia were excluded be-
cause they do not receive pulsed treatment, and those with a
brain tumor were excluded if they required cranial irradiation,
which could affect the hypothalamic-pituitary-gonadal axis. Pa-
tients with a gonadal tumor or primary gonadal dysgenesis were
also excluded. Consecutive eligible patients were approached.
Only one eligible patient declined study entry due to parental
concerns about introducing discussions regarding fertility at the
time of diagnosis.
Pubertal status was assessed clinically at diagnosis and was
classified as prepubertal (Tanner stage 1), midpuberty (Tanner
stage 2/3), or late puberty (Tanner stage 4/5) (21). Patients were
also classified according to their predicted risk of future gonado-
toxicity (low, medium, or high), based on chemotherapy agent,
cumulative dose and radiotherapy involving the ovaries,without
knowledge of hormone results. This classification was based on
an assessment of the risk of subfertility according to the cancer
diagnosis, stage of the disease, and treatment delivered (22). Low
risk was estimated as less than 20% probability of future sub-
fertility, medium risk between 20 and 80%, and high risk at
greater than 80% (22).
All participants or their guardians providedwritten informed
consent. Ethical approval was obtained from Lothian Research
Ethics Committee.
Blood sampling was performed at diagnosis, as a baseline,
and then before and after each cycle of chemotherapy for the
duration of treatment. Treatment usually comprised four or
more chemotherapy cycles. Follow-up samples were obtained a
minimum of 6 months after completion of treatment.
Blood was collected into lithium heparin tubes and plasma
subsequently stored at 20 C to 80 C until analysis. AMH
(activeMullerian inhibiting substance/AMH)and inhibinBwere
measuredusing sensitivedouble-antibodyELISA (bothBeckman
Coulter,Chaska,MN)as previously described (14, 16). FSHwas
measured by time-resolved immunofluorimetric assay (Delfia,
Wallac, Milton Keynes, UK). Assay detection limits were 0.05
ng/ml forAMH,10pg/ml for inhibin B, and0.07U/liter for FSH.
Intra- and interassay coefficients of variation for AMH, inhibin
B, andFSHwere less than10%.All samples fromeach individual
patient were analyzed in the same analytical run to minimize
variation.
Data analysis
Nonparametric statistics were used. Hormone results below
the detection limit were expressed as the detection limit for sta-
tistical analysis and graphical display. Results are presented as
median (range). Spearman rank correlation was used to test the
relationship of hormoneswith age. Longitudinal changes in hor-
mones with time during treatment were assessed by the Kruskal-
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Wallis test. Changes during follow-up were assessed by Wil-
coxon signed-rank tests. Mann-Whitney U tests were used to
compare hormonal results by risk of gonadotoxicity. As AMH
riseswith age, SD z-scoreswere calculated to correct for this from
our published nomogram (9). AMH concentrations pretreat-
ment and during follow-up were also assessed for age-adjusted
normality (i.e. that they lay within age specific 95% confidence
intervals). Additional analyses following classification by risk
were performed after log transformation of the data, using Stu-
dent’s t test or ANOVA and post hocDunnett’s test for multiple
groups, with pretreatment data as the comparator.
Results
Twenty-two female patients were recruited at the time of
diagnosis (Table1).Medianagewas4.4 (range0.3–15) yr,
with 17 being prepubertal. In 15 patients treatment in-
cluded alkylating agents and seven patients received cis-
platin. Six patients received radiotherapy to a field that
included both ovaries. Radiotherapy was delivered after
the completion of chemotherapy in all six patients except
for one patient (patient 6), who received emergency radio-
therapy to the spinebecauseof cord compressiondeveloping
shortly after commencing treatment. The predicted risk of
future gonadotoxicity, based on a chemotherapy agent, cu-
mulative dose, and radiotherapy involving the ovaries, was
low in five patients, medium in eight patients, and high in
nine patients (Table 1) (22). Posttreatment follow-up sam-
ples were collected in 16 patients; of the remaining six pa-
tients, threehaddied, twowereundergoingfurthertreatment
TABLE 1. Subject characteristics (cyclophos  cyclophosphamide)
Subject Diagnosis
Gonadotoxic
chemotherapy
Cumulative
dose
Radiotherapy
to ovaries
Gonadotoxic
risk Outcome
Pubertal
stage at
start
Age
at start
(yr)
Age at
completion of
treatment (yr)
Duration of
follow-up
(months)
Prepubertal
1 Hepatoblastoma Cisplatin 14 mg/kga No Medium Alive Pre 0.3 0.8 6
2 Germ cell tumour — No Low Alive Pre 0.9 1.3 25
3 Stage 4 neuroblastoma Cisplatin 163 mg/m2 No High Alive Pre 1.2 1.8 8
Cyclophos 6.2 g/m2
Melphalan 180 mg/m2
4 Langerhans cell
histiocytosis
— No Low Relapse Alive Pre 1.2 1.9
5 Germ cell tumour — No Low Alive Pre 1.4 1.8 23
6 Stage 4 neuroblastoma Cisplatin 320 mg/m2 Yes, spine High Relapsed Alive Pre 1.9 5.1 25
Cyclophos 4.2 g/m2
Melphalan 180 mg/m2
7 Retinoblastoma — No Low Alive Pre 2.1 2.4
8 Stage 4 Neuroblastoma Cisplatin 320 mg/m2 No High Died Pre 2.1 2.5
Cyclophos 4.5 g/m2
Melphalan 180 mg/m2
9 Rhabdomyosarcoma Ifosfamide 54 g/m2 No Medium Alive Pre 2.4 3.0 31
10 Wilms — No Low Alive Pre 3.5 4.2 42
11 Rhabdomyosarcoma Ifosfamide 54 g/m2 No Medium Alive Pre 3.9 4.3 37
12 Stage 4 neuroblastoma Cisplatin 320 mg/m2 Yes, abdomen High Secondary AML
age 8y -died
Pre 4.9 5.3
Cyclophos 4.2 g/m2
Melphalan 140 mg/m2
13 Rhabdomyosarcoma Ifosfamide 54 g/m2 Yes, direct High Alive Pre 5.2 6.3 25
Cyclophos 6 g/m2
14 Stage 4 neuroblastoma Cisplatin 320 mg/m2 Yes, abdomen High Died Pre 6.6 7.3
Cyclophos 6.6 g/m2
15 Rhabdomyosarcoma Ifosfamide 60 g/m2 No Medium Alive Pre 7.0 7.5 34
16 Rhabdomyosarcoma Ifosfamide 36 g/m2 Yes, direct High Relapsed Died Pre 7.2 7.5 19
Cyclophos 7.5 g/m2
17 Metastatic Ewing’s
sarcoma
Ifosfamide 60 g/m2 Yes, direct High Alive Pre 9.9 10.4 12
Melphalan 140 mg/m2
Pubertal
18 Metastatic osteosarcoma Cisplatin 720 mg/m2 No Medium Died Mid 13.7 14.8
Ifosfamide 27 g/m2
19 Hodgkin’s disease Procarbazine 3.4 g/m2 No Medium Alive Late 13.6 14.1 43
Chlorambucil 210 mg/m2
Vinblastine 32 mg/m2
Dacarbazine 2 g/m2
20 T-cell lymphoma Ifosfamide 8 g/m2 No Medium Alive Late 14.3 14.7 34
Vinblastine 24 mg/m2
Cyclophos 2.4 g/m2
21 Hodgkin’s disease Procarbazine 4.2 g/m2 No Medium Alive Late 14.6 15.1 24
Chlorambucil 210 mg/m2
Vinblastine 30 mg/m2
Dacarbazine 2.3 g/m2
22 Metastatic
rhabdomyosarcoma
Cyclophos 29 g/m2 No High Died Late 15.0 16.1 4
Ifosfamide 9 g/m2
—, No gonadotoxic agent administered; Pre, prepubuertal.
a Dose recorded as per kilogram body weight rather than surface area in view of young age of patient, according to standard chemotherapy
prescribing guidelines.
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due to relapse, and one patient declined further blood
sampling.
Pretreatment AMH was detectable in all patients, me-
dian1.27 (range0.11–3.75) ng/ml.Therewas a significant
positive relationship with age (r  0.87, P  0.001), but
no such relationship with age was seen for inhibin B or
FSH (r 0.3 and 0.18, respectively, both not significant).
At diagnosis, inhibin B was detectable (55–122 pg/ml) in
only five girls, aged 0.3–14.3 yr. Baseline FSH was 1.27
(0.13–5.04) U/liter.
MedianAMHfell progressively during treatment, from
1.27 (0.11–3.75 ng/ml) to 0.05 ng/ml (0.05–0.90 ng/ml;
P 0.001, Fig. 1, A and B) over the first six cycles. AMH
fell in both prepubertal (1.06 to 0.05 ng/ml at end of treat-
ment, P  0.002) and pubertal (1.40–0.36 ng/ml, P 
0.001) girls.Age-adjustedAMHanalysis (Fig. 1B) showed
thatAMHwas slightly but not significantly belowaverage
(i.e. a negative z score) before treatment and fell to an
average of 1.5 SD during treatment.
In the five girls inwhom inhibinBwasdetectable before
treatment, it decreased from a median of 105 (55–122)
ng/ml to 30 (10 to 50) ng/ml after four cycles of treat-
ment (P 0.05; data available on only two girls after six
cycles, Fig. 1C). It remained undetectable in those girls in
whom it was undetectable before treatment. FSH showed
no significant change over this period (median pretreat-
mentFSH1.27U/liter, 1.57U/liter after course6, Fig. 1D).
It is possible that the data from the two
youngest girls (aged 0.3 and 0.9 yr be-
fore treatment) might have been influ-
enced by the neonatal rise in reproduc-
tive hormones; however, both showed
similar changes to the rest of the cohort
(i.e. declining AMHwith treatment, no
consistent change in FSH), and exclud-
ing them did not alter the results.
After completion of treatment, there
was biochemical evidence of recovery
ofovarian functiondetectedby changes
in AMH but not inhibin B or FSH (Fig.
2). Follow-up samples were grouped as
taken between 2 and 12 months after
completing treatment and beyond 12
months. Median AMH rose progres-
sively from 0.09 (0.05 to 2.25) ng/ml
at the end of treatment to 0.44 (0.05
to 3.66) ng/ml at 2–12months (not sig-
nificant) and to 1.40 (0.05 to 2.72)
ng/ml at longer than 12months, similar
to pretreatment concentrations and sig-
nificantly higher than at the end of
treatment (P  0.01, Fig. 2A). How-
ever, this recovery was not observed in
all girls. In five girls in whom AMH was undetectable at
the end of treatment, it remained so during follow-up (pa-
tients 3, 6, 13, 17, and 22). All of these had been classified
as being at high risk of gonadotoxicity, including three
whohad received radiotherapy involving the ovaries. Two
other girls (one with a germ cell tumor, patient 5, and one
with Wilms’ tumor, patient 10, both classified as at low
risk of gonadotoxicity) had undetectable AMH at the end
of treatment but demonstrated recovery to detectable con-
centrations thereafter. Examples of changes in AMH in
individuals are shown in Fig. 3. These all show a fall in
AMHduring treatment, with recovery in two prepubertal
girls (Fig. 3, A and B; classified as low and medium risk,
respectively) to concentrations higher than before treat-
ment, probably reflecting the progressive rise in AMH
during childhood. Absent recovery in two prepubertal
girls is shown in Fig. 3, C and D (both high risk), and
partial recovery in two pubertal girls are shown in Fig. 3,
E and F (both classified as medium risk).
Analysis of inhibin B data are limited by the small num-
ber of girls with detectable inhibin B concentrations at
diagnosis (Fig. 2B). Of these five, inhibin B was undetect-
able at the end of treatment in two girls (patients 9 and 19)
and remained so during follow-up. Two girls showed re-
covery in inhibin B during follow-up.One girl with a germ
cell tumor (patient 2) had an atypical pattern with fluc-
A B
C D
FIG. 1. AMH (A), AMH z-score (B), inhibin B (C) and FSH (D) concentrations before treatment
(Pre) and after each of the first six courses of chemotherapy. Note that inhibin B data are from
only those girls in whom it was detectable before treatment. Median  interquartile range,
except AMH z-score, are mean  SEM. AMH and FSH, n  22; inhibin B, n  5 (data included
only where inhibin B was detectable in pretreatment sample). AMH: **, P  0.01, ***, P 
0.001 vs. pretreatment concentration. Inhibin B: bar and asterisk denote significant difference
by ANOVA (P  0.05). Individual cycle data were not significantly different from
pretreatment.
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tuating inhibin B during treatment, followed by a decrease
to an undetectable level after treatment.
FSH showed no overall changes during recovery (Fig.
2C). Two of the girls had clearly elevated concentrations
of FSH greater than 10 U/liter, indicating gonadal failure;
both had undetectable AMHat end of treatment andwere
classified as at high riskof gonadotoxicity (patients 17and
22). There was no significant relationship between AMH
and FSH at any time point, although there was a trend
toward a negative correlation at the end of follow-up (r
0.51, P  0.07).
Data were also analyzed by estimated degree of go-
nadotoxicity of the treatment administered (seeMaterials
andMethods and Table 1). Nine girls were classified as at
high risk, eight at medium risk, and five at low risk. Due
to the similarity of the hormone data in the medium- and
low-risk groups, these were combined for analysis. AMH
fell to undetectable concentrations in all girls in the high-
risk group and subsequently showed no recovery
(ANOVAP 0.002; Fig. 4A). AMHalso fell significantly
during treatment in the medium/low-risk group, but this
was followed by a significant rise during recovery (end of
treatment vs. recovery: P 0.005). Although AMH con-
centrationswere similar in the high- andmedium/low-risk
groups at diagnosis, at the end of treatment there were
clear differences in AMH concentration between these
groups (P 0.001). This difference persisted into the fol-
low-up period with lower AMH concentrations in the
high-risk group (P 0.003). There was, however, no ev-
idence for amore rapid fall inAMHin thehigh-risk group,
with the fall in AMHbecoming significant after treatment
cycle 2 in both groups. AMH concentrations during fol-
low-up were also assessed for age-related normality and
were low (z score less than 2) in three girls in the medi-
um-risk group [patients 19 and 21, both with Hodgkin’s
lymphoma (data shown in Fig. 3, E and F), and patient 11,
with a rhabdomyosarcoma] and none in the low-risk
group.
FSH concentrations at diagnosis or end of treatment
did not differ by risk (Fig. 4B) but were higher in the high-
risk group at follow-up (P  0.04). Because of the small
numberof girlswithdetectable inhibinBconcentrations at
diagnosis, analysis by gonadotoxic risk stratification was
not possible.
The cohort will be followed up long term, but thus far
two patients who were prepubertal at recruitment have
confirmed premature ovarian failure with significant ele-
vation of FSH on several occasions (patients 13 and 17).
Both are in the high gonadotoxicity risk group and had
undetectable AMH during chemotherapy and immedi-
ately after treatment (data frompatient 17 are represented
in Fig. 3D) but with no associated elevation of FSH at that
time.
Discussion
This is the first study we are aware of to measure AMH
prospectively from diagnosis to follow up in a pediatric
cancer cohort. We have shown that AMH falls during
cancer treatment in both prepubertal and pubertal girls.
Subsequent recovery was apparent in the majority of girls
after the end of treatment but in those deemed to be at
highest risk of ovarian failure recovery was absent up to 3
yr after treatment. Hormonal changes in the youngest
might have been complicated by the neonatal rises in FSH
and AMH (6, 23); however, the changes in the two girls
A
B
C
FIG. 2. AMH (A), inhibin B (B), and FSH (C) concentrations before
treatment (Pre), at the end of treatment, and at 2–12 months and at
more than 12 months’ recovery after treatment. Median 
interquartile range. AMH and FSH, n  22; inhibin B, n  5. *, P 
0.05 vs. pretreatment; **, P  0.05 vs. end of treatment.
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aged younger than 1 yr were comparable with those in
older girls.Our findings suggest thatAMHmaybeauseful
marker of ovarian reserve in younggirls treated for cancer.
This will have implications for counseling patients before
and after treatment and may be helpful in defining which
young patients may benefit from pretreatment ovarian
cryopreservation.
Significant advances have been made over recent de-
cades in the treatment of childhood cancer (1). This im-
provement has, in part, resulted from intensification of
cytotoxic treatment modalities, particularly with regard
to multiagent and high-dose chemotherapy. Although
overall survival has increased, so too have adverse effects
of treatment, both in the short and long term. The impact
of treatment on future fertility is of significant concern,
both to parents and patients (24), but it is difficult to pre-
dict accurately future fertility, and guidelines based on
agent and dose are relatively crude (22). Radiotherapy to
a field that includes theovaries is gonadotoxic
inadose-dependent fashion(4).However, the
impact of chemotherapy can be much more
difficult to determine. It is known that certain
chemotherapeutic agents, such as alkylating
agents, are gonadotoxic, but the degree of
ovarian damage can be very variable and the
mechanisms are poorly understood (25). Al-
though patients receiving chemotherapy may
retain fertility, their menopause may be pre-
mature, reflecting an accelerated decline in
oocyte numbers (2, 3). Thus, their windowof
fertility may be shortened (26).
An accurate marker of future reproduc-
tive function, which can be measured lon-
gitudinally before, during, and after treat-
ment, would be of significant benefit to
these patients and their families. AMHwas
detectable in all pretreatment samples, in
contrast to inhibin B. This reflects the dif-
ferent growth stages of ovarian follicles pro-
ducing these hormones. AMH is produced
during early stages of follicle growth (7),
whereas inhibin-producing stages are later
and more gonadotrophin sensitive, and this
hormone is consistently detectable only af-
ter puberty (27). Our data confirm a pro-
gressive rise in AMH during childhood and
adolescence (6, 9) and demonstrate a fall
during cancer treatment, which was readily
detectable in both prepubertal and postpu-
bertal girls. AMH concentrations at the end
of treatment reflectedgonadotoxicity, being
significantly lower inthehigh-riskgroup,con-
firming the value of AMH as a quantitative
index of the damage to the ovarian reserve. Furthermore,
differential recovery after treatmentwas also identified,with
AMH remaining undetectable in the high-risk group,
whereas girls in the low- and medium-risk groups showed
recovery to concentrations similar to thosebefore treatment.
Whether this translates to a normal duration of reproduc-
tive life span will require very long-term follow-up. The
recovery in AMH after chemotherapy indicates restora-
tion of the pool of small growing follicles, which in turn
reflects the size on the nongrowing, primordial pool (28).
The decline in AMH during chemotherapy reflects in-
creased follicular atresia (29), and during follow-up the
normal pattern of early follicle growth, present in girls of
all ages (30), will be restored. Thus, the absence of a re-
covery in the high-risk groups indicates a profound loss of
the primordial follicle pool unable to generate sufficient
small growing follicles to secrete a detectable amount of
A B
C D
E F
FIG. 3. Representative AMH concentrations in individual girls during and after
chemotherapy showing suppression of AMH in both prepubertal (A–D) and pubertal (E
and F) girls, with no posttreatment recovery in girls who received high-risk treatment (C
and D). The duration of chemotherapy is denoted by the solid bar at the top of each
panel. A, patient 5, 1.4 yr; B, patient 9, 2.4 yr; C, patient 3, 1.2 yr; D, patient 17, 9.9 yr;
E, patient 19, 13.6 yr; F, patient 21, 14.6 yr. Both axes have different scales in different
panels, reflecting variation in pretreatment AMH and duration of follow-up.
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AMH. AMH concentrations rise through childhood and
adolescence, with an intriguing inflection at the start of
puberty, despite the declining size of the primordial pool
(6, 9, 31). The relationship between them therefore
changes across the reproductive life span (32). Some cau-
tion is thus required in comparison of their relationships
between for example the neonatal period, childhood, and
adulthood. However, the dramatic differences in end of
treatment and recovery phase AMH concentrations be-
tween groups demonstrated here supports a clear conclu-
sion that there are substantial differences between chemo-
therapy regimens in their effects on the ovarian reserve.
A recent study from The Netherlands showed that in a
cohort of childhood cancer survivors, AMHwas reduced
in those predicted to be at high risk of gonadal damage
(19). Our study confirms these findings and demonstrates
that AMH reflects ovarian damage after chemotherapy,
and this can be detected before puberty or traditional ev-
idence of premature ovarian failure, with elevated FSH
concentrations and low estradiol. AMH may thus repre-
sent a reliable and accurate marker of gonadotoxicity sec-
ondary to cancer treatment.
In contrast, our data suggest that inhibin B and FSHare
not helpful within the prepubertal age group. A previous
pilot study suggested that inhibin B might be a potential
marker for gonadotoxicity in prepubertal girls (20), but
this has not been confirmed here.We found that inhibin B
was undetectable in the majority of prepubertal girls at
diagnosis, reflecting the very lowgonadal activity after the
neonatal “minipuberty” (33) until puberty it-
self. In those patients in whom inhibin B was
detectable, it did, like AMH, show a progres-
sive decrease during successive treatment
courses inmost cases,with recovery during fol-
low-up in a proportion of patients. However,
the lack of reliable sensitivity of this marker in
prepubertal girls and its marked variation (un-
like AMH) during the menstrual cycle in post-
pubertal girls limit its use as a marker of go-
nadotoxicity in children and adolescents.
Whereas in postpubertal patients raised
FSH concentrations represent a very useful in-
dicator of ovarian failure, the quiescence of the
hypothalamic-pituitary-gonadal axis in the
prepubertal age group predicts that FSH is of
limited value in prepubertal girls. Our data
confirm this. Although FSH did rise during
treatment in many (but not all) patients in our
study and indicated gonadal failure in one pa-
tient, with a trend towards recovery on fol-
low-up in most cases, this hormone did not
discriminate sufficiently to function as a
marker of gonadotoxicity in children.
A limitation of this study is the relatively small number
of patients. However, the marked decline in AMH con-
centrations in response to cytotoxic treatment, with re-
covery in those patients stratified to be at lower risk of
longer-term gonadotoxicity, indicates its value in moni-
toring ovarian function before, during, and after cancer
treatment in the prepubertal age group. The cohort of
patients who were assessed to be at high risk of ovarian
toxicity in whom there was no recovery of AMH after
treatment was completed require further long-term fol-
low-up to confirm that they have failed to recover their
ovarian function. However, it is of note that of the four
girls in the high-risk group who are still alive, two have
confirmed premature ovarian failure. The remaining two
are still at prepubertal ages at the present time.
A marker of ovarian function, particularly in the pre-
pubertal age group, would improve future identification
of those towhomfertilitypreservation strategies shouldbe
addressed. Ovarian cryopreservation as a method of re-
storing fertility after gonadotoxic treatment is becoming
increasingly used and is the only method appropriate to
prepubertal girls (34–36), andcriteriahavebeenproposed
as a guide to indicate to whom ovarian cryopreservation
should be offered (36–38). However, the experience
within one center would suggest that these selection cri-
teria do not necessarily target the desired patient group
(36). Improved individualization of risk, for which some
data are now available supporting the value of AMH in
A
B
FIG. 4. AMH (A) and FSH (B) concentrations before treatment (Pre), at the end of
treatment, and at more than 6 months’ recovery after treatment. Patients were
stratified according to predicted risk of gonadotoxicity. Median  interquartile
range, n  9, high risk; n  13, medium/low risk. †, P  0.01 vs. pretreatment;
*, P  0.05 and **, P  0.01 vs. end of treatment.
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adult cancer patient care (16), is particularly important in
children in whom an invasive laparoscopic procedure is
required to collect ovarian tissue for cryopreservation.
In conclusion, this is the first prospective studyofAMH
in girls receiving treatment for childhood cancer and pro-
vides evidence that serum AMH concentrations could be
a clinically useful marker of the size of the remaining fol-
licle pool (the ovarian reserve) after cancer in pre- and
postpubertal girls.
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